This page has only limited features, please log in for full access.
Barbara Obermayer-Pietsch, MD, is Professor of Endocrinology and Osteology at the Medical University Graz, Division of Endocrinology and Diabetology. As an expert in translational research for glucose and mineral metabolism, androgens, microbiome and fertility, she is head of the Endocrinology Lab Platform for hormonal and metabolic analyses in clinical care and research and head of the EndoGeneLab. Her publications show more than 8000 citations, h-index of 49; about 60 diploma and doctoral theses have been completed. Beyond international positions, she is currently president of the Austrian Society of Endocrinology and Metabolism and of the Austrian Platform for Personalized Medicine.
In burn injuries, risk factors and limitations to treatment success are difficult to assess clinically. However, local cellular responses are characterized by specific gene-expression patterns. MicroRNAs (miRNAs) are single-stranded, non-coding RNAs that regulate mRNA expression on a posttranscriptional level. Secreted through exosome-like vesicles (ELV), miRNAs are intracellular signalers and epigenetic regulators. To date, their role in the regulation of the early burn response remains unclear. Here, we identified 43 miRNAs as potential regulators of the early burn response through the bioinformatics analysis of an existing dataset. We used an established human ex vivo skin model of a deep partial-thickness burn to characterize ELVs and miRNAs in dermal interstitial fluid (dISF). Moreover, we identified miR-497-5p as stably downregulated in tissue and dISF in the early phase after a burn injury. MiR-218-5p and miR-212-3p were downregulated in dISF, but not in tissue. Target genes of the miRNAs were mainly upregulated in tissue post-burn. The altered levels of miRNAs in dISF of thermally injured skin mark them as new biomarker candidates for burn injuries. To our knowledge, this is the first study to report miRNAs altered in the dISF in the early phase of deep partial-thickness burns.
Ines Foessl; Christoph Walter Haudum; Ivan Vidakovic; Ruth Prassl; Joakim Franz; Selma I. Mautner; Sonja Kainz; Elisabeth Hofmann; Barbara Obermayer-Pietsch; Thomas Birngruber; Petra Kotzbeck. miRNAs as Regulators of the Early Local Response to Burn Injuries. International Journal of Molecular Sciences 2021, 22, 9209 .
AMA StyleInes Foessl, Christoph Walter Haudum, Ivan Vidakovic, Ruth Prassl, Joakim Franz, Selma I. Mautner, Sonja Kainz, Elisabeth Hofmann, Barbara Obermayer-Pietsch, Thomas Birngruber, Petra Kotzbeck. miRNAs as Regulators of the Early Local Response to Burn Injuries. International Journal of Molecular Sciences. 2021; 22 (17):9209.
Chicago/Turabian StyleInes Foessl; Christoph Walter Haudum; Ivan Vidakovic; Ruth Prassl; Joakim Franz; Selma I. Mautner; Sonja Kainz; Elisabeth Hofmann; Barbara Obermayer-Pietsch; Thomas Birngruber; Petra Kotzbeck. 2021. "miRNAs as Regulators of the Early Local Response to Burn Injuries." International Journal of Molecular Sciences 22, no. 17: 9209.
The Cytochrome P450 CYP1A2 is a central enzyme in the metabolism of drugs and xenobiotics. The overall activity of this enzyme is influenced by a complex array of biochemical, dietary, and genetic factors. One of the simplest ways to probe the overall output of CYP1A2 is to measure the ratio between the concentration of a precursor and a product of its activity. With the growing interest in the Paraxanthine/Caffeine ratio, the need arises to develop improved analytical methods specifically optimized for the rapid and sensitive determination of paraxanthine and caffeine in biological samples. We report a new optimized method for the determination of caffeine and paraxanthine in various human matrices. The method involved direct determination following protein precipitation based on ultra high performance liquid chromatographic separation with tandem mass spectrometric detection (UHPLC-ESIMS/MS). The method offers an improvement in the detection limit over previously published methods by at least 10-fold (0.1 pg), rapid chromatographic separation (ca. 5 min), the utilization of a green chromatographic solvent (5% v/v ethanol), direct determination with little sample preparation, and the employment of isotopically labeled internal standards and qualifier ions to ensure accuracy. Method validation in urine, saliva, and plasma was performed by spiking at various concentration levels where the recovery and repeatability were within ±15% and ±10%, respectively. The method was applied to investigate the levels of caffeine and paraxanthine in volunteers following controlled caffeine administration and to investigate the inter- and intra-individual variability in the paraxanthine/caffeine ratio in volunteers following an unrestricted caffeine diet. In conclusion, the developed UHPLC-ESIMS/MS method is optimized specifically for the simultaneous determination of the paraxanthine/caffeine ratio in multiple biological matrices, offers several advantages over the current methods, and is well suitable for application in large clinical studies.
Bassam Lajin; Natascha Schweighofer; Walter Goessler; Barbara Obermayer-Pietsch. The determination of the Paraxanthine/Caffeine ratio as a metabolic biomarker for CYP1A2 activity in various human matrices by UHPLC-ESIMS/MS. Talanta 2021, 234, 122658 .
AMA StyleBassam Lajin, Natascha Schweighofer, Walter Goessler, Barbara Obermayer-Pietsch. The determination of the Paraxanthine/Caffeine ratio as a metabolic biomarker for CYP1A2 activity in various human matrices by UHPLC-ESIMS/MS. Talanta. 2021; 234 ():122658.
Chicago/Turabian StyleBassam Lajin; Natascha Schweighofer; Walter Goessler; Barbara Obermayer-Pietsch. 2021. "The determination of the Paraxanthine/Caffeine ratio as a metabolic biomarker for CYP1A2 activity in various human matrices by UHPLC-ESIMS/MS." Talanta 234, no. : 122658.
Ein Erratum zu dieser Publikation wurde veröffentlicht: 10.1007/s41969-021-00135-y
Valentin Borzan; Anna Mayr; Barbara Obermayer-Pietsch. Erratum zu: Das polyzystische Ovar-Syndrom – Entstehung, Behandlung und neue Erkenntnisse. Journal für Klinische Endokrinologie und Stoffwechsel 2021, 14, 88 -88.
AMA StyleValentin Borzan, Anna Mayr, Barbara Obermayer-Pietsch. Erratum zu: Das polyzystische Ovar-Syndrom – Entstehung, Behandlung und neue Erkenntnisse. Journal für Klinische Endokrinologie und Stoffwechsel. 2021; 14 (2):88-88.
Chicago/Turabian StyleValentin Borzan; Anna Mayr; Barbara Obermayer-Pietsch. 2021. "Erratum zu: Das polyzystische Ovar-Syndrom – Entstehung, Behandlung und neue Erkenntnisse." Journal für Klinische Endokrinologie und Stoffwechsel 14, no. 2: 88-88.
Zusammenfassung Das polyzystische Ovar-Syndrom (PCOS) ist die häufigste Endokrinopathie bei Frauen im gebärfähigen Alter. In den letzten Jahren gab es zahlreiche Fortschritte im Verständnis zu Definition, Pathogenese und Behandlungsmöglichkeiten. Diese Übersichtsarbeit gibt Einblick in diese Erkenntnisse und erläutert mögliche neue Therapiezweige anhand der aktuellen Literatur. Die Symptome des PCOS sind vielfältig und ihre Ausprägung entlang eines breiten Spektrums verteilt. Die wichtigsten klinischen Hinweise sind Hirsutismus, Oligo‑/Amenorrhö, Infertilität sowie Insulinresistenz, Übergewicht/Adipositas und die namensgebenden polyzystischen Ovarien. Da es keine ursächliche Therapie für das Syndrom gibt, sollte die symptomatische Behandlung mit der Patientin und ihren Bedürfnissen abgestimmt werden. Die wichtigsten Therapiemöglichkeiten sind Lebensstilinterventionen, Metformin, hormonelle Kontrazeptiva, (hormonelle) Ovulationsinduktoren sowie chirurgische Eingriffe. In den letzten Jahren haben sich mit dem Zusammenhang von Darmmikrobiom, Hormonen und Energiestoffwechsel weitere potenzielle Behandlungsmöglichkeiten aufgetan, deren Einfluss aktuell untersucht wird. Probiotika könnten dabei helfen, hormonelle und metabolische Prozesse zu modifizieren und dadurch PCOS-typische Symptome zu lindern.
Valentin Borzan; Anna Mayr; Barbara Obermayer-Pietsch. Das polyzystische Ovar-Syndrom – Entstehung, Behandlung und neue Erkenntnisse. Journal für Klinische Endokrinologie und Stoffwechsel 2021, 14, 81 -87.
AMA StyleValentin Borzan, Anna Mayr, Barbara Obermayer-Pietsch. Das polyzystische Ovar-Syndrom – Entstehung, Behandlung und neue Erkenntnisse. Journal für Klinische Endokrinologie und Stoffwechsel. 2021; 14 (2):81-87.
Chicago/Turabian StyleValentin Borzan; Anna Mayr; Barbara Obermayer-Pietsch. 2021. "Das polyzystische Ovar-Syndrom – Entstehung, Behandlung und neue Erkenntnisse." Journal für Klinische Endokrinologie und Stoffwechsel 14, no. 2: 81-87.
Zusammenfassung Die Notwendigkeit einer Langzeittherapie bei Osteoporose, eine teils eingeschränkte Compliance, aber auch die Möglichkeit von erheblichen Nebenwirkungen bei einer pharmakologischen Osteoporosetherapie beschäftigen sowohl die medizinischen Richtlinien als auch die Betroffenen in vielfacher Weise. In dieser Übersicht wird auf den Stand der zur Verfügung stehenden Osteoporosepharmazeutika und die aktuellen wissenschaftlich fundierten Grundlagen einer langjährigen Anwendung, das potenzielle Monitoring und mögliche Therapieänderungen mit dem spezifischen Augenmerk auf künftige Entwicklungen eingegangen.
Barbara Obermayer-Pietsch; Ines Fössl; Hans Peter Dimai. Langfristige Therapiekonzepte bei Osteoporose. Der Internist 2021, 62, 474 -485.
AMA StyleBarbara Obermayer-Pietsch, Ines Fössl, Hans Peter Dimai. Langfristige Therapiekonzepte bei Osteoporose. Der Internist. 2021; 62 (5):474-485.
Chicago/Turabian StyleBarbara Obermayer-Pietsch; Ines Fössl; Hans Peter Dimai. 2021. "Langfristige Therapiekonzepte bei Osteoporose." Der Internist 62, no. 5: 474-485.
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in premenopausal women, with a wide spectrum of possible phenotypes, symptoms and sequelae according to the current clinical definition. However, there are women who do not fulfill at least two out of the three commonly used “Rotterdam criteria” and their risk of developing type 2 diabetes or obesity later in life is not defined. Therefore, we addressed this important gap by conducting a retrospective analysis based on 750 women with and without PCOS. We compared four different PCOS phenotypes according to the Rotterdam criteria with women who exhibit only one Rotterdam criterion and with healthy controls. Hormone and metabolic differences were assessed by analysis of variance (ANOVA) as well as logistic regression analysis. We found that hyperandrogenic women have per se a higher risk of developing insulin resistance compared to phenotypes without hyperandrogenism and healthy controls. In addition, hyperandrogenemia is associated with developing insulin resistance also in women with no other Rotterdam criterion. Our study encourages further diagnostic and therapeutic approaches for PCOS phenotypes in order to account for varying risks of developing metabolic diseases. Finally, women with hyperandrogenism as the only symptom should also be screened for insulin resistance to avoid later metabolic risks.
Valentin Borzan; Elisabeth Lerchbaum; Cornelia Missbrenner; Annemieke Heijboer; Michaela Goschnik; Christian Trummer; Verena Theiler-Schwetz; Christoph Haudum; Roswitha Gumpold; Natascha Schweighofer; Barbara Obermayer-Pietsch. Risk of Insulin Resistance and Metabolic Syndrome in Women with Hyperandrogenemia: A Comparison between PCOS Phenotypes and Beyond. Journal of Clinical Medicine 2021, 10, 829 .
AMA StyleValentin Borzan, Elisabeth Lerchbaum, Cornelia Missbrenner, Annemieke Heijboer, Michaela Goschnik, Christian Trummer, Verena Theiler-Schwetz, Christoph Haudum, Roswitha Gumpold, Natascha Schweighofer, Barbara Obermayer-Pietsch. Risk of Insulin Resistance and Metabolic Syndrome in Women with Hyperandrogenemia: A Comparison between PCOS Phenotypes and Beyond. Journal of Clinical Medicine. 2021; 10 (4):829.
Chicago/Turabian StyleValentin Borzan; Elisabeth Lerchbaum; Cornelia Missbrenner; Annemieke Heijboer; Michaela Goschnik; Christian Trummer; Verena Theiler-Schwetz; Christoph Haudum; Roswitha Gumpold; Natascha Schweighofer; Barbara Obermayer-Pietsch. 2021. "Risk of Insulin Resistance and Metabolic Syndrome in Women with Hyperandrogenemia: A Comparison between PCOS Phenotypes and Beyond." Journal of Clinical Medicine 10, no. 4: 829.
Vitamin D (VD) might play an important role in polycystic ovary syndrome (PCOS) and female fertility. However, evidence from randomized controlled trials (RCT) is sparse. We examined VD effects on anti-Müllerian hormone (AMH) and other endocrine markers in PCOS and non-PCOS women. This is a post hoc analysis of a single-center, double-blind RCT conducted between December 2011 and October 2017 at the endocrine outpatient clinic at the Medical University of Graz, Austria. We included 180 PCOS women and 150 non-PCOS women with serum 25-hydroxyvitamin D (25(OH)D) concentrations p = 0.031) and LH/FSH ratio (mean treatment effect −0.335, 95% CI −0.621 to 0.050, p = 0.022), whereas no significant effect was observed in non-PCOS women. In PCOS women, VD treatment for 24 weeks had a significant effect on FSH and LH/FSH ratio but no effect on AMH levels.
Elisabeth Lerchbaum; Verena Theiler-Schwetz; Martina Kollmann; Monika Wölfler; Stefan Pilz; Barbara Obermayer-Pietsch; Christian Trummer. Effects of Vitamin D Supplementation on Surrogate Markers of Fertility in PCOS Women: A Randomized Controlled Trial. Nutrients 2021, 13, 547 .
AMA StyleElisabeth Lerchbaum, Verena Theiler-Schwetz, Martina Kollmann, Monika Wölfler, Stefan Pilz, Barbara Obermayer-Pietsch, Christian Trummer. Effects of Vitamin D Supplementation on Surrogate Markers of Fertility in PCOS Women: A Randomized Controlled Trial. Nutrients. 2021; 13 (2):547.
Chicago/Turabian StyleElisabeth Lerchbaum; Verena Theiler-Schwetz; Martina Kollmann; Monika Wölfler; Stefan Pilz; Barbara Obermayer-Pietsch; Christian Trummer. 2021. "Effects of Vitamin D Supplementation on Surrogate Markers of Fertility in PCOS Women: A Randomized Controlled Trial." Nutrients 13, no. 2: 547.
Studies suggest that non-pregnant women with polycystic ovary syndrome (PCOS) may be at elevated risk of 25 hydroxyvitamin D (25(OH)D) deficiency. Furthermore, there is evidence suggesting that 25(OH)D may also play an important role during pregnancy. Data regarding 25(OH)D deficiency during pregnancy in PCOS patients and its association with perinatal outcome is scarce. The aim of the study was to investigate whether mothers with and without PCOS have different 25(OH)D levels at term, how maternal 25(OH)D levels are reflected in their offspring, and if 25(OH)D levels are associated with an adverse perinatal outcome. Therefore, we performed a cross-sectional observational study and included 79 women with PCOS according to the ESHRE/ASRM 2003 definition and 354 women without PCOS and an ongoing pregnancy ≥ 37 + 0 weeks of gestation who gave birth in our institution between March 2013 and December 2015. Maternal serum and cord blood 25(OH)D levels were analyzed at the day of delivery. Maternal 25(OH)D levels did not differ significantly in women with PCOS and without PCOS (p = 0.998), nor did the 25(OH)D levels of their respective offspring (p = 0.692). 25(OH)D deficiency (p = 0.430). There was a strong positive correlation between maternal and neonatal 25(OH)D levels in both investigated groups (r ≥ 0.79, p < 0.001). Linear regression estimates of cord blood 25(OH)D levels are about 77% of serum 25(OH)D concentrations of the mother. Compared to healthy controls, the risk for maternal complications was increased in PCOS women (48% vs. 65%; p = 0.009), while there was no significant difference in neonatal complications (22% and 22%; p = 1.0). However, 25(OH)D levels were similar between mothers and infants with and without perinatal complications. Although the share of women and infants with 25(OH)D deficiency was high in women with PCOS and without PCOS, it seems that the incidence of adverse perinatal outcome was not affected. The long-term consequences for mothers and infants with a 25(OH)D deficiency have to be investigated in future studies.
Martina Kollmann; Barbara Obermayer-Pietsch; Elisabeth Lerchbaum; Sarah Feigl; Rüdiger Hochstätter; Gudrun Pregartner; Christian Trummer; Philipp Klaritsch. Vitamin D Concentrations at Term Do Not Differ in Newborns and Their Mothers with and without Polycystic Ovary Syndrome. Journal of Clinical Medicine 2021, 10, 537 .
AMA StyleMartina Kollmann, Barbara Obermayer-Pietsch, Elisabeth Lerchbaum, Sarah Feigl, Rüdiger Hochstätter, Gudrun Pregartner, Christian Trummer, Philipp Klaritsch. Vitamin D Concentrations at Term Do Not Differ in Newborns and Their Mothers with and without Polycystic Ovary Syndrome. Journal of Clinical Medicine. 2021; 10 (3):537.
Chicago/Turabian StyleMartina Kollmann; Barbara Obermayer-Pietsch; Elisabeth Lerchbaum; Sarah Feigl; Rüdiger Hochstätter; Gudrun Pregartner; Christian Trummer; Philipp Klaritsch. 2021. "Vitamin D Concentrations at Term Do Not Differ in Newborns and Their Mothers with and without Polycystic Ovary Syndrome." Journal of Clinical Medicine 10, no. 3: 537.
Background: Posttraumatic stress disorder (PTSD) is a frequently observed stress-related disorder after acute myocardial infarction (AMI) and it is characterized by numerous symptoms, such as flashbacks, intrusions and anxiety, as well as uncontrollable thoughts and feelings related to the trauma. Biological correlates of severe stress might contribute to identifying PTSD-vulnerable patients at an early stage. Objective: Aims of the study were (1) to determine whether blood levels of trimethylamine N-oxide (TMAO) vary immediately after AMI in patients with/without AMI-induced PTSD symptomatology, (2) to investigate whether TMAO is a potential biomarker that might be useful in the prediction of PTSD and the PTSD symptom subclusters re-experiencing, avoidance and hyperarousal, and (3) to investigate whether TMAO varies immediately after AMI in patients with/without depression 6 months after AMI. Method: A total of 114 AMI patients were assessed with the Hamilton-Depression Scale after admission to the hospital and 6 months later. The Clinician Administered PTSD Scale for DSM-5 was used to explore PTSD-symptoms at the time of AMI and 6 months after AMI. To assess patients’ TMAO status, serum samples were collected at hospitalization and 6 months after AMI. Results: Participants with PTSD-symptomatology had significantly higher TMAO levels immediately after AMI than patients without PTSD-symptoms (ANCOVA: TMAO(PTSD x time), F = 4.544, df = 1, p = 0.035). With the inclusion of additional clinical predictors in a hierarchical logistic regression model, TMAO became a significant predictor of PTSD-symptomatology. No significant differences in TMAO levels immediately after AMI were detected between individuals with/without depression 6 months after AMI. Conclusions: An elevated TMAO level immediately after AMI might reflect severe stress in PTSD-vulnerable patients, which might also lead to a short-term increase in gut permeability to trimethylamine, the precursor of TMAO. Thus, an elevated TMAO level might be a biological correlate for severe stress that is associated with vulnerability to PTSD.
Andreas Baranyi; Dietmar Enko; Dirk von Lewinski; Hans-Bernd Rothenhäusler; Omid Amouzadeh-Ghadikolai; Hanns Harpf; Leonhard Harpf; Heimo Traninger; Barbara Obermayer-Pietsch; Melanie Schweinzer; Celine K. Braun; Andreas Meinitzer. Assessment of trimethylamine N-oxide (TMAO) as a potential biomarker of severe stress in patients vulnerable to posttraumatic stress disorder (PTSD) after acute myocardial infarction. European Journal of Psychotraumatology 2021, 12, 1 .
AMA StyleAndreas Baranyi, Dietmar Enko, Dirk von Lewinski, Hans-Bernd Rothenhäusler, Omid Amouzadeh-Ghadikolai, Hanns Harpf, Leonhard Harpf, Heimo Traninger, Barbara Obermayer-Pietsch, Melanie Schweinzer, Celine K. Braun, Andreas Meinitzer. Assessment of trimethylamine N-oxide (TMAO) as a potential biomarker of severe stress in patients vulnerable to posttraumatic stress disorder (PTSD) after acute myocardial infarction. European Journal of Psychotraumatology. 2021; 12 (1):1.
Chicago/Turabian StyleAndreas Baranyi; Dietmar Enko; Dirk von Lewinski; Hans-Bernd Rothenhäusler; Omid Amouzadeh-Ghadikolai; Hanns Harpf; Leonhard Harpf; Heimo Traninger; Barbara Obermayer-Pietsch; Melanie Schweinzer; Celine K. Braun; Andreas Meinitzer. 2021. "Assessment of trimethylamine N-oxide (TMAO) as a potential biomarker of severe stress in patients vulnerable to posttraumatic stress disorder (PTSD) after acute myocardial infarction." European Journal of Psychotraumatology 12, no. 1: 1.
Background: Polycystic ovary syndrome (PCOS) affects 5–20% of women of reproductive age worldwide and is associated with disorders of glucose metabolism. Hormone and metabolic signaling may be influenced by phytoestrogens, such as isoflavones. Their endocrine effects may modify symptom penetrance in PCOS. Equol is one of the most active isoflavone metabolites, produced by intestinal bacteria, and acts as a selective estrogen receptor modulator. Method: In this interventional study of clinical and biochemical characterization, urine isoflavone levels were measured in PCOS and control women before and three days after a defined isoflavone intervention via soy milk. In this interventional study, bacterial equol production was evaluated using the log(equol: daidzein ratio) and microbiome, metabolic, and predicted metagenome analyses were performed. Results: After isoflavone intervention, predicted stool metagenomic pathways, microbial alpha diversity, and glucose homeostasis in PCOS improved resembling the profile of the control group at baseline. In the whole cohort, larger equol production was associated with lower androgen as well as fertility markers. Conclusion: The dynamics in our metabolic, microbiome, and predicted metagenomic profiles underline the importance of external phytohormones on PCOS characteristics and a potential therapeutic approach or prebiotic in the future.
Christoph Haudum; Lisa Lindheim; Angelo Ascani; Christian Trummer; Angela Horvath; Julia Münzker; Barbara Obermayer-Pietsch. Impact of Short-Term Isoflavone Intervention in Polycystic Ovary Syndrome (PCOS) Patients on Microbiota Composition and Metagenomics. Nutrients 2020, 12, 1 .
AMA StyleChristoph Haudum, Lisa Lindheim, Angelo Ascani, Christian Trummer, Angela Horvath, Julia Münzker, Barbara Obermayer-Pietsch. Impact of Short-Term Isoflavone Intervention in Polycystic Ovary Syndrome (PCOS) Patients on Microbiota Composition and Metagenomics. Nutrients. 2020; 12 (6):1.
Chicago/Turabian StyleChristoph Haudum; Lisa Lindheim; Angelo Ascani; Christian Trummer; Angela Horvath; Julia Münzker; Barbara Obermayer-Pietsch. 2020. "Impact of Short-Term Isoflavone Intervention in Polycystic Ovary Syndrome (PCOS) Patients on Microbiota Composition and Metagenomics." Nutrients 12, no. 6: 1.
Purpose: Organic cation transporters (Octs) use cations like endogenous compounds, toxins, and drugs, such as metformin, as substrates. Therefore, these proteins determine the pharmacokinetics and -dynamics of metformin and thus its efficacy. Of note, metformin is today the most commonly used pharmaceutical in the treatment of type 2 diabetes (T2DM) with nevertheless a great variability in clinical response, which attributes to genetic variances. The aim of this study was to determine the influence of intronic OCT1 SNPs on prevalence of all-cause and cardiovascular death. Patients and Methods: Genotypes of 27 intronic SNPs in OCT1 were investigated in the LURIC study, a prospective cohort of 3316 participants scheduled for coronary angiography. We investigated whether these variants were associated with all-cause and cardiovascular death in 73 individuals with T2DM under metformin therapy, in individuals without diabetes, individuals with T2DM and individuals with T2DM without metformin therapy. Results: In a multivariate Cox regression analysis adjusted for classical cardiovascular risk factors, 4 intronic OCT1 SNPs were significantly associated with all-cause and cardiovascular mortality in individuals with T2DM on metformin therapy. Conclusion: According to their OCT1 genotype, some individuals with T2DM on metformin therapy might be prone to an increased risk of cardiovascular death.
Natascha Schweighofer; Bernd Genser; Winfried Maerz; Marcus E Kleber; Olivia Trummer; Thomas R Pieber; Barbara Obermayer-Pietsch. Intronic Variants in OCT1 are Associated with All-Cause and Cardiovascular Mortality in Metformin Users with Type 2 Diabetes. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2020, ume 13, 2069 -2080.
AMA StyleNatascha Schweighofer, Bernd Genser, Winfried Maerz, Marcus E Kleber, Olivia Trummer, Thomas R Pieber, Barbara Obermayer-Pietsch. Intronic Variants in OCT1 are Associated with All-Cause and Cardiovascular Mortality in Metformin Users with Type 2 Diabetes. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2020; ume 13 ():2069-2080.
Chicago/Turabian StyleNatascha Schweighofer; Bernd Genser; Winfried Maerz; Marcus E Kleber; Olivia Trummer; Thomas R Pieber; Barbara Obermayer-Pietsch. 2020. "Intronic Variants in OCT1 are Associated with All-Cause and Cardiovascular Mortality in Metformin Users with Type 2 Diabetes." Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy ume 13, no. : 2069-2080.
The 25-Hydroxyvitamin D (25[OH)D) serum concentration depends on vitamin D intake, endogenous vitamin D production and genetic factors. The latter have been demonstrated in large genome-wide association studies indicating that single nucleotide polymorphisms (SNPs) in genes related to the vitamin D metabolism are as important for serum 25(OH)D levels as the influence of season. The mechanism on how these SNPs influence serum 25(OH)D levels are still unclear. The aim of the present study was to investigate the genetic effects of ten selected SNPs related to vitamin D metabolism on 25-hydroxyvitamin D increase (∆25(OH)D) after vitamin D supplementation in three randomized controlled trials. Genotypes of SNPs related to vitamin D metabolism were determined in 411 participants with 25(OH)D concentrations < 75 nmol/l receiving 20,000 IU cholecalciferol per week for 8 or 12 weeks after study inclusion. For the vitamin D receptor (VDR) rs10783219 polymorphism, the minor A-allele was associated with lower ∆25(OH)D values in the entire study population (p = 0.022), which was not consistent in all three cohorts when analysed separately. VDR rs10783219 might therefore be a genetic modulator of increasing 25-hydroxyvitamin D concentrations. Considering the wide-spread use of vitamin D supplementation, future large and well-designed randomized controlled trials (RCTs) should investigate the clinical impact of this polymorphism.
Olivia Trummer; Natascha Schweighofer; Christoph W. Haudum; Christian Trummer; Stefan Pilz; Verena Theiler-Schwetz; Martin H. Keppel; Martin Grübler; Thomas R. Pieber; Wilfried Renner; Barbara Obermayer-Pietsch; Elisabeth Lerchbaum. Genetic Components of 25-Hydroxyvitamin D Increase in Three Randomized Controlled Trials. Journal of Clinical Medicine 2020, 9, 570 .
AMA StyleOlivia Trummer, Natascha Schweighofer, Christoph W. Haudum, Christian Trummer, Stefan Pilz, Verena Theiler-Schwetz, Martin H. Keppel, Martin Grübler, Thomas R. Pieber, Wilfried Renner, Barbara Obermayer-Pietsch, Elisabeth Lerchbaum. Genetic Components of 25-Hydroxyvitamin D Increase in Three Randomized Controlled Trials. Journal of Clinical Medicine. 2020; 9 (2):570.
Chicago/Turabian StyleOlivia Trummer; Natascha Schweighofer; Christoph W. Haudum; Christian Trummer; Stefan Pilz; Verena Theiler-Schwetz; Martin H. Keppel; Martin Grübler; Thomas R. Pieber; Wilfried Renner; Barbara Obermayer-Pietsch; Elisabeth Lerchbaum. 2020. "Genetic Components of 25-Hydroxyvitamin D Increase in Three Randomized Controlled Trials." Journal of Clinical Medicine 9, no. 2: 570.
Barbara Obermayer-Pietsch; Elisabeth Lerchbaum. Polyzystisches Ovar-Syndrom (PCOS). Journal für Klinische Endokrinologie und Stoffwechsel 2019, 12, 170 -173.
AMA StyleBarbara Obermayer-Pietsch, Elisabeth Lerchbaum. Polyzystisches Ovar-Syndrom (PCOS). Journal für Klinische Endokrinologie und Stoffwechsel. 2019; 12 (4):170-173.
Chicago/Turabian StyleBarbara Obermayer-Pietsch; Elisabeth Lerchbaum. 2019. "Polyzystisches Ovar-Syndrom (PCOS)." Journal für Klinische Endokrinologie und Stoffwechsel 12, no. 4: 170-173.
Objectives: The aetiology of polycystic ovary syndrome (PCOS) is not particularly mapped; however, a complex interaction of various factors, such as genetic, environmental and intrauterine factors, can be assumed. Experimental animal studies and clinical observations support the hypothesis that developmental programming by excess intrauterine steroid is relevant. The aim of the study was to investigate whether mothers with and without PCOS exhibit different androgen and anti-Mullerian hormone (AMH) levels at the end of pregnancy and how maternal hormone levels are reflected in their offspring. Methods: Between March 2013 and December 2015, we performed a prospective cross-sectional study at the Medical University of Graz. We included 79 women with PCOS according to the ESHRE/ASRM 2003 definition and 354 women without PCOS, both with an ongoing pregnancy ≥37 + 0 weeks of gestation, who gave birth in our institution. Primary outcome parameters were the levels of maternal and neonatal androgens (testosterone, free testosterone, androstenedione) and AMH at delivery. Results: Androgen levels in female offspring of PCOS and non-PCOS women at birth did not differ, while maternal hormone levels differed significantly. Androgen levels in PCOS boys were significantly higher when compared to levels in PCOS girls. Discussion: Our findings do not support the hypothesis that maternal androgen excess contributes to elevated androgen concentrations in the female offspring. Nevertheless, the effects of the increased androgen concentrations in mothers on their offspring have to be investigated in future studies.
Martina Kollmann; Barbara Obermayer-Pietsch; Elisabeth Lerchbaum; Uwe Lang; Sereina A. Herzog; Christian Trummer; Anna Scheuchenegger; Daniela Ulrich; Philipp Klaritsch. Androgen and Anti-Mullerian Hormone Concentrations at Term in Newborns and Their Mothers with and without Polycystic Ovary Syndrome. Journal of Clinical Medicine 2019, 8, 1817 .
AMA StyleMartina Kollmann, Barbara Obermayer-Pietsch, Elisabeth Lerchbaum, Uwe Lang, Sereina A. Herzog, Christian Trummer, Anna Scheuchenegger, Daniela Ulrich, Philipp Klaritsch. Androgen and Anti-Mullerian Hormone Concentrations at Term in Newborns and Their Mothers with and without Polycystic Ovary Syndrome. Journal of Clinical Medicine. 2019; 8 (11):1817.
Chicago/Turabian StyleMartina Kollmann; Barbara Obermayer-Pietsch; Elisabeth Lerchbaum; Uwe Lang; Sereina A. Herzog; Christian Trummer; Anna Scheuchenegger; Daniela Ulrich; Philipp Klaritsch. 2019. "Androgen and Anti-Mullerian Hormone Concentrations at Term in Newborns and Their Mothers with and without Polycystic Ovary Syndrome." Journal of Clinical Medicine 8, no. 11: 1817.
25-hydroxyvitamin D (25(OH)D) is commonly measured to assess vitamin D status. Other vitamin D metabolites such as 24,25-dihydroxyvitamin D (24,25(OH)2D) provide additional insights into vitamin D status or metabolism. Earlier studies suggested that the vitamin D metabolite ratio (VMR), calculated as 24,25(OH)2D/25(OH)D, could predict the 25(OH)D increase after vitamin D supplementation. However, the evidence for this additional value is inconclusive. Therefore, our aim was to assess whether the increase in 25(OH)D after supplementation was predicted by the VMR better than baseline 25(OH)D. Plasma samples of 106 individuals (25(OH)D < 75 nmol/L) with hypertension who completed the Styrian Vitamin D Hypertension Trial (NC.T.02136771) were analyzed. Participants received vitamin D (2800 IU daily) or placebo for 8 weeks. The treatment effect (ANCOVA) for 25(OH)D3, 24,25(OH)2D3 and the VMR was 32 nmol/L, 3.3 nmol/L and 0.015 (all p < 0.001), respectively. Baseline 25(OH)D3 and 24,25(OH)2D3 predicted the change in 25(OH)D3 with comparable strength and magnitude. Correlation and regression analysis showed that the VMR did not predict the change in 25(OH)D3. Therefore, our data do not support routine measurement of 24,25(OH)2D3 in order to individually optimize the dosage of vitamin D supplementation. Our data also suggest that activity of 24-hydroxylase increases after vitamin D supplementation.
Vito Francic; Stan R. Ursem; Niek F. Dirks; Martin H. Keppel; Verena Theiler-Schwetz; Christian Trummer; Marlene Pandis; Valentin Borzan; Martin R. Grübler; Nicolas D. Verheyen; Winfried März; Andreas Tomaschitz; Stefan Pilz; Annemieke C. Heijboer; Barbara Obermayer-Pietsch. The Effect of Vitamin D Supplementation on its Metabolism and the Vitamin D Metabolite Ratio. Nutrients 2019, 11, 2539 .
AMA StyleVito Francic, Stan R. Ursem, Niek F. Dirks, Martin H. Keppel, Verena Theiler-Schwetz, Christian Trummer, Marlene Pandis, Valentin Borzan, Martin R. Grübler, Nicolas D. Verheyen, Winfried März, Andreas Tomaschitz, Stefan Pilz, Annemieke C. Heijboer, Barbara Obermayer-Pietsch. The Effect of Vitamin D Supplementation on its Metabolism and the Vitamin D Metabolite Ratio. Nutrients. 2019; 11 (10):2539.
Chicago/Turabian StyleVito Francic; Stan R. Ursem; Niek F. Dirks; Martin H. Keppel; Verena Theiler-Schwetz; Christian Trummer; Marlene Pandis; Valentin Borzan; Martin R. Grübler; Nicolas D. Verheyen; Winfried März; Andreas Tomaschitz; Stefan Pilz; Annemieke C. Heijboer; Barbara Obermayer-Pietsch. 2019. "The Effect of Vitamin D Supplementation on its Metabolism and the Vitamin D Metabolite Ratio." Nutrients 11, no. 10: 2539.
Vitamin D might play a role in metabolic processes and obesity. We therefore examined vitamin D effects on metabolic markers and obesity in a randomized controlled trial (RCT). This is a post-hoc analysis of the Graz Vitamin D&TT-RCT, a single-center, double-blind, randomized placebo-controlled trial. We included 200 healthy men with serum 25-hydroxyvitamin D (25(OH) D) levels
Elisabeth Lerchbaum; Christian Trummer; Verena Theiler-Schwetz; Martina Kollmann; Monika Wölfler; Stefan Pilz; Barbara Obermayer-Pietsch. Effects of Vitamin D Supplementation on Body Composition and Metabolic Risk Factors in Men: A Randomized Controlled Trial. Nutrients 2019, 11, 1894 .
AMA StyleElisabeth Lerchbaum, Christian Trummer, Verena Theiler-Schwetz, Martina Kollmann, Monika Wölfler, Stefan Pilz, Barbara Obermayer-Pietsch. Effects of Vitamin D Supplementation on Body Composition and Metabolic Risk Factors in Men: A Randomized Controlled Trial. Nutrients. 2019; 11 (8):1894.
Chicago/Turabian StyleElisabeth Lerchbaum; Christian Trummer; Verena Theiler-Schwetz; Martina Kollmann; Monika Wölfler; Stefan Pilz; Barbara Obermayer-Pietsch. 2019. "Effects of Vitamin D Supplementation on Body Composition and Metabolic Risk Factors in Men: A Randomized Controlled Trial." Nutrients 11, no. 8: 1894.
Vitamin D is well known for its effects on calcium and mineral metabolism. However, vitamin D effects on bone turnover markers (BTMs), which are used together with bone mineral density (BMD) to evaluate bone health, are less clear. We therefore examined vitamin D effects on BTMs (beta-cross laps (CTX) and osteocalcin (OC)) and BMD in a post-hoc analysis of a randomized controlled trial (RCT). This is a post-hoc analysis of the Graz Vitamin D&TT-RCT, a single-center, double-blind, randomized placebo-controlled trial conducted between December 2012 and November 2017 at the endocrine outpatient clinic at the Medical University of Graz, Austria. A total of 200 healthy men with serum 25-hydroxyvitamin D (25(OH)D) levels 0.05 for all). In middle-aged healthy men, vitamin D treatment for 12 weeks had no significant effect on BTMs or BMD.
Elisabeth Lerchbaum; Christian Trummer; Verena Theiler-Schwetz; Martina Kollmann; Monika Wölfler; Stefan Pilz; Barbara Obermayer-Pietsch. Effects of Vitamin D Supplementation on Bone Turnover and Bone Mineral Density in Healthy Men: A Post-Hoc Analysis of a Randomized Controlled Trial. Nutrients 2019, 11, 731 .
AMA StyleElisabeth Lerchbaum, Christian Trummer, Verena Theiler-Schwetz, Martina Kollmann, Monika Wölfler, Stefan Pilz, Barbara Obermayer-Pietsch. Effects of Vitamin D Supplementation on Bone Turnover and Bone Mineral Density in Healthy Men: A Post-Hoc Analysis of a Randomized Controlled Trial. Nutrients. 2019; 11 (4):731.
Chicago/Turabian StyleElisabeth Lerchbaum; Christian Trummer; Verena Theiler-Schwetz; Martina Kollmann; Monika Wölfler; Stefan Pilz; Barbara Obermayer-Pietsch. 2019. "Effects of Vitamin D Supplementation on Bone Turnover and Bone Mineral Density in Healthy Men: A Post-Hoc Analysis of a Randomized Controlled Trial." Nutrients 11, no. 4: 731.
Vitamin D supplementation may affect glycemic as well as hormonal regulation. Thus, the aim of the current study was to investigate whether vitamin D supplementation has any significant effects on metabolic and endocrine parameters in healthy premenopausal women. Primary outcome measure was the plasma glucose area under the curve (AUCgluc). The current study was a single-center, double-blind, randomized placebo-controlled trial that was conducted at the Medical University of Graz, Austria, between March 2013 and October 2017. One-hundred and fifty healthy premenopausal women with 25-hydroxyvitamin D [25(OH)D] concentrations <75 nmol/L once weekly received either 20,000 IU of cholecalciferol or placebo (2:1 ratio) over a total of 24 weeks. In total, 127 women [age 36.2 ± 8.7 years; BMI 25.3 ± 5.6 kg/m2; baseline 25(OH)D 55.8 ± 19.7 nmol/L] completed the study. Vitamin D supplementation had no significant effect on AUCgluc (mean treatment effect 11.70; p = 0.069), while it had a significant treatment effect on homeostatic model assessment-insulin resistance (HOMA-IR; mean treatment effect 0.31; p = 0.019) and quantitative insulin-sensitivity check index (QUICKI; mean treatment effect −0.019; p = 0.013). There was no significant effect on the remaining secondary outcome parameters. In this randomized-controlled trial in healthy premenopausal women, there was a significant treatment effect of vitamin D supplementation on HOMA-IR and QUICKI, while there was no significant treatment effect on AUCgluc.
Christian Trummer; Verena Theiler-Schwetz; Martina Kollmann; Monika Wölfler; Julia Münzker; Stefan Pilz; Thomas R. Pieber; Annemieke C. Heijboer; Barbara Obermayer-Pietsch; Elisabeth Lerchbaum. Effects of vitamin D supplementation on metabolic and endocrine parameters in healthy premenopausal women: A randomized controlled trial. Clinical Nutrition 2019, 39, 718 -726.
AMA StyleChristian Trummer, Verena Theiler-Schwetz, Martina Kollmann, Monika Wölfler, Julia Münzker, Stefan Pilz, Thomas R. Pieber, Annemieke C. Heijboer, Barbara Obermayer-Pietsch, Elisabeth Lerchbaum. Effects of vitamin D supplementation on metabolic and endocrine parameters in healthy premenopausal women: A randomized controlled trial. Clinical Nutrition. 2019; 39 (3):718-726.
Chicago/Turabian StyleChristian Trummer; Verena Theiler-Schwetz; Martina Kollmann; Monika Wölfler; Julia Münzker; Stefan Pilz; Thomas R. Pieber; Annemieke C. Heijboer; Barbara Obermayer-Pietsch; Elisabeth Lerchbaum. 2019. "Effects of vitamin D supplementation on metabolic and endocrine parameters in healthy premenopausal women: A randomized controlled trial." Clinical Nutrition 39, no. 3: 718-726.
Polycystic ovary syndrome (PCOS) is a common endocrine and metabolic disorder of unclear etiology in women and is characterized by androgen excess, insulin resistance, and mood disorders. The gut microbiome is known to influence conditions closely related with PCOS, and several recent studies have observed changes in the stool microbiome of women with PCOS. The mechanism by which the gut microbiome interacts with PCOS is still unknown.We used a mouse model to investigate if diet-induced maternal obesity and maternal DHT exposure, mimicking the lean and obese PCOS women, cause lasting changes in the gut microbiome of offspring. Fecal microbiome profiles were assessed using Illumina paired-end sequencing of 16S rRNA gene V4 amplicons.We found sex-specific effects of maternal and offspring diet, and maternal DHT exposure on fecal bacterial richness and taxonomic composition. Female offspring exposed to maternal obesity and DHT displayed reproductive dysfunction and anxietylike behavior. Fecal microbiota transplantation from DHT and diet-induced obesity exposed female offspring to wild-type mice did not transfer reproductive dysfunction and did not cause the expected increase in anxietylike behavior in recipients.Maternal obesity and androgen exposure affect the gut microbiome of offspring, but the disrupted estrous cycles and anxietylike behavior are likely not microbiome-mediated.
Lisa Lindheim; Maria Manti; Romina Fornes; Mina Bashir; Paulo Czarnewski; Oscar E Diaz; Maike Seifert; Lars Engstrand; Eduardo J Villablanca; Barbara Obermayer-Pietsch; Elisabet Stener-Victorin. Reproductive and Behavior Dysfunction Induced by Maternal Androgen Exposure and Obesity Is Likely Not Gut Microbiome-Mediated. Journal of the Endocrine Society 2018, 2, 1363 -1380.
AMA StyleLisa Lindheim, Maria Manti, Romina Fornes, Mina Bashir, Paulo Czarnewski, Oscar E Diaz, Maike Seifert, Lars Engstrand, Eduardo J Villablanca, Barbara Obermayer-Pietsch, Elisabet Stener-Victorin. Reproductive and Behavior Dysfunction Induced by Maternal Androgen Exposure and Obesity Is Likely Not Gut Microbiome-Mediated. Journal of the Endocrine Society. 2018; 2 (12):1363-1380.
Chicago/Turabian StyleLisa Lindheim; Maria Manti; Romina Fornes; Mina Bashir; Paulo Czarnewski; Oscar E Diaz; Maike Seifert; Lars Engstrand; Eduardo J Villablanca; Barbara Obermayer-Pietsch; Elisabet Stener-Victorin. 2018. "Reproductive and Behavior Dysfunction Induced by Maternal Androgen Exposure and Obesity Is Likely Not Gut Microbiome-Mediated." Journal of the Endocrine Society 2, no. 12: 1363-1380.
Glucocorticoids are regulators of stress response essential for survival. Liver disease can alter this homeostatic mechanism in patients with liver cirrhosis – a finding that might mirror the controversially discussed condition of critical illness related corticosteroid insufficiency. Underlying mechanisms might be shared molecular pathways in both bile acid as well as glucocorticoid metabolism at the level of synthesis, catabolism or the hypothalamus and the pituitary gland. Molecular links include the farnesoid X receptor FXR or the G protein-coupled bile acid receptor TGR5 expressed in the liver and the adrenals. In this review we sum up knowledge on the regulation of adrenal gland function and steroidogenesis, focussing on bile acids and potential alterations under cholestatic conditions, depict molecular links between glucocorticoid and bile acid metabolism and discuss the difficulties of assessment of adrenal function in humans in general and more specifically in liver diseases.
Verena Theiler-Schwetz; Alex Zaufel; Hansjörg Schlager; Barbara Obermayer-Pietsch; Peter Fickert; Gernot Zollner. Bile acids and glucocorticoid metabolism in health and disease. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2018, 1865, 243 -251.
AMA StyleVerena Theiler-Schwetz, Alex Zaufel, Hansjörg Schlager, Barbara Obermayer-Pietsch, Peter Fickert, Gernot Zollner. Bile acids and glucocorticoid metabolism in health and disease. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2018; 1865 (1):243-251.
Chicago/Turabian StyleVerena Theiler-Schwetz; Alex Zaufel; Hansjörg Schlager; Barbara Obermayer-Pietsch; Peter Fickert; Gernot Zollner. 2018. "Bile acids and glucocorticoid metabolism in health and disease." Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1865, no. 1: 243-251.